ACROSTUDY: The first 5 years

Peter J. Trainer

doi:10.1530/EJE-09-0322

ACROSTUDY: The first 5 years

Peter J. Trainer

Research output: Contribution to journal › Article › peer-review

Abstract

ACROSTUDY is an observational registry intended to collect safety and efficacy data on pegvisomant therapy. A total of 792 patients have been enrolled, of whom 83% had commenced pegvisomant prior to recruitment. The mean follow-up is 1.66 years with the mean duration of pegvisomant therapy 3.31 years representing 2625 patient years of treatment. About 90% of patients were on once daily pegvisomant, and 67% were on monotherapy. Disappointingly, IGF1 was normalised in

Original language	English
Pages (from-to)	S19-S24
Journal	European Journal of Endocrinology
Volume	161
Issue number	1
DOIs	https://doi.org/10.1530/EJE-09-0322
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1530/EJE-09-0322

http://www.eje-online.org/cgi/reprint/161/S1/S19

Cite this

@article{9af75c8aa6944f62bb3700fd82fa8e1e,

title = "ACROSTUDY: The first 5 years",

abstract = "ACROSTUDY is an observational registry intended to collect safety and efficacy data on pegvisomant therapy. A total of 792 patients have been enrolled, of whom 83% had commenced pegvisomant prior to recruitment. The mean follow-up is 1.66 years with the mean duration of pegvisomant therapy 3.31 years representing 2625 patient years of treatment. About 90% of patients were on once daily pegvisomant, and 67% were on monotherapy. Disappointingly, IGF1 was normalised in",

author = "Trainer, {Peter J.}",

year = "2009",

doi = "10.1530/EJE-09-0322",

language = "English",

volume = "161",

pages = "S19--S24",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - ACROSTUDY: The first 5 years

AU - Trainer, Peter J.

PY - 2009

Y1 - 2009

N2 - ACROSTUDY is an observational registry intended to collect safety and efficacy data on pegvisomant therapy. A total of 792 patients have been enrolled, of whom 83% had commenced pegvisomant prior to recruitment. The mean follow-up is 1.66 years with the mean duration of pegvisomant therapy 3.31 years representing 2625 patient years of treatment. About 90% of patients were on once daily pegvisomant, and 67% were on monotherapy. Disappointingly, IGF1 was normalised in

AB - ACROSTUDY is an observational registry intended to collect safety and efficacy data on pegvisomant therapy. A total of 792 patients have been enrolled, of whom 83% had commenced pegvisomant prior to recruitment. The mean follow-up is 1.66 years with the mean duration of pegvisomant therapy 3.31 years representing 2625 patient years of treatment. About 90% of patients were on once daily pegvisomant, and 67% were on monotherapy. Disappointingly, IGF1 was normalised in

U2 - 10.1530/EJE-09-0322

DO - 10.1530/EJE-09-0322

M3 - Article

C2 - 19684052

SN - 0804-4643

VL - 161

SP - S19-S24

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 1

ER -

ACROSTUDY: The first 5 years

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this